Should drug holidays be implemented for patients on Boniva (ibandronate)?

Drug Holidays for Boniva (Ibandronate)

Yes, you should consider a drug holiday after 5 years of Boniva treatment, but only if the patient is no longer at high fracture risk (T-score > -2.5, no fractures during treatment, and low-to-moderate ongoing fracture risk). 1

Treatment Duration Before Considering a Holiday

For oral bisphosphonates like Boniva, the AACE 2020 guidelines specifically recommend:

• Consider a drug holiday after 5 years if fracture risk is no longer high 1
• Continue treatment up to 10 years if fracture risk remains high 1
• For very high-risk patients, consider a holiday only after 6-10 years of stability 1

The Endocrine Society 2019 guidelines align with this, recommending fracture risk reassessment after 3-5 years of bisphosphonate therapy, with drug holidays considered for those at low-to-moderate risk 2

Who Should Get a Drug Holiday

Appropriate candidates:

• T-score improved to greater than -2.5 1
• Remained fracture-free during treatment 1
• No longer meet high-risk criteria (FRAX hip fracture risk <3% or major osteoporotic fracture risk <20%) 1
• Completed at least 5 years of oral bisphosphonate therapy 1

Continue treatment (no holiday) if:

• T-score remains ≤ -2.5 at the femoral neck 1
• History of fragility fractures, especially vertebral 1
• Very high fracture risk (advanced age, frailty, glucocorticoid use, very low T-scores, increased fall risk) 1
• Experienced fractures during treatment 1

Critical Caveat: Ibandronate-Specific Considerations

Important limitation: The evidence for drug holidays is strongest for alendronate and zoledronic acid, where randomized extension trials exist 2. The guidelines note that evidence for ibandronate is more limited 3. Ibandronate has weaker bone binding affinity than alendronate or zoledronic acid, suggesting potentially shorter residual effects during a holiday 4.

Real-world data shows that risedronate users experienced more frequent fractures during drug holidays than alendronate users due to faster offset of antiresorptive effect 5. Given ibandronate's similar or potentially weaker binding profile, closer monitoring is warranted during an ibandronate holiday compared to alendronate.

Duration of the Drug Holiday

While no definitive duration is established for ibandronate specifically, extrapolating from the bisphosphonate class:

• 1-2 years may be appropriate initially, given ibandronate's potentially shorter residual effect 3
• Reassess every 2-4 years during the holiday 2
• Maximum holiday duration up to 5 years has been suggested for oral bisphosphonates generally 2

Monitoring During the Holiday

Resume treatment immediately if: 1, 4

• New fracture occurs (any fragility fracture)
• BMD declines beyond the least significant change (LSC) of your DXA machine (typically 3-5% at spine, 4-6% at hip)
• Bone turnover markers rise to pretreatment values (though this is debatable and may not apply to all patients)
• Fracture risk increases due to new risk factors (falls, glucocorticoid initiation, etc.)

Monitoring schedule:

• DXA scan every 2 years during the holiday 2
• Consider bone turnover markers (CTX or P1NP) at baseline of holiday and periodically 1
• Annual clinical assessment for new fractures, falls, and risk factor changes 1

What NOT to Do

Never implement a drug holiday for non-bisphosphonate antiresorptives 1:

• Denosumab: Stopping causes rapid bone loss and rebound vertebral fractures; must transition to another antiresorptive if discontinuing 2, 1, 2
• Raloxifene, estrogen, SERMs: No residual effect after discontinuation 6
• Teriparatide: Limited to 2 years total; must follow with antiresorptive 1

Real-World Evidence

Studies show 40% higher fracture risk in patients taking bisphosphonate drug holidays compared to those continuing treatment 7. However, this must be balanced against the goal of reducing rare but serious adverse events (atypical femoral fractures, osteonecrosis of the jaw) associated with prolonged use. The key is appropriate patient selection—holidays are safest in those who have achieved low-to-moderate fracture risk through treatment.

Practical Algorithm

1. After 5 years of Boniva: Reassess fracture risk (DXA, FRAX, fracture history)
2. If T-score > -2.5 AND no fractures AND low-moderate FRAX: Consider 1-2 year holiday initially
3. If T-score ≤ -2.5 OR prior fractures OR high FRAX: Continue treatment
4. During holiday: DXA every 2 years, clinical assessment annually
5. Resume if: New fracture, BMD decline beyond LSC, or increased fracture risk
6. Maximum holiday: Reassess at 2-4 years; consider resuming by 5 years given ibandronate's potentially shorter residual effect

1, 2, 1, 2, 1, 2, 4, 3, 7, 5